9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Estimated reading time: < 1 min

Condition: Advanced Malignant Solid Neoplasm

Estimated Enrollment: 58

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Dose-limiting toxicity (Arm A),  Response rate (Arm B),  Pharmacokinetic (PK) parameter, Establishment of pleural and peritoneal effluent-derived cell lines

Interventions: Cisplatin, Methoxyamine

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: December 31, 2019

Completion Date:

Last  Posted Date: June 11, 2019

Location: City of Hope Comprehensive Cancer Center, Duarte, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02535312

Was this article helpful?
Dislike 0